Editing Controlled Substances Act (section)

===Schedule V===
<!-- DO NOT MOVE THE ABOVE ANCHOR TAG. See detailed comment under the "Schedule I" section. -->
{{Main|List of Schedule V drugs (US)}}

Schedule V substances are those that have the following findings:
{{blockquote|1=
{{ordered list|type=A
 |The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV
 |The drug or other substance has a currently accepted medical use in treatment in the United States
 |Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.<ref name="cornell1"/>
}}}}

No controlled substance in Schedule V which is a drug may be distributed or dispensed other than for a medical purpose.<ref name="cornell2"/> A prescription for controlled substances in Schedules III, IV, and V issued by a practitioner, may be communicated either orally, in writing, electronically transmitted or by facsimile to the pharmacist, and may be refilled if so authorized on the prescription or by call-in.<ref name="deadiversion.usdoj.gov"/>

Drugs in this schedule include:
* Cough suppressants containing small amounts of codeine (e.g., [[promethazine]]+codeine);
* Preparations containing small amounts of opium or [[diphenoxylate]] (used to treat diarrhea);
* Some [[anticonvulsant]]s, such as [[pregabalin]] (Lyrica), [[lacosamide]] (Vimpat), [[brivaracetam]] (Briviact), and [[retigabine]] ([[ezogabine]]) (Potiga/Trobalt);
* [[Pyrovalerone]] (used to treat [[Fatigue#Chronic|chronic fatigue]] and as an [[appetite suppressant]] for [[weight loss]]);
* Some centrally-acting antidiarrheals, such as [[diphenoxylate]] (Lomotil) when mixed with [[atropine]] (to make it poisonous, if taken at euphoria-inducing dosages). [[Difenoxin]] with atropine (Motofen) has been moved to Schedule IV. Without atropine, these drugs are in Schedule II.
* [[Cannabidiol]], only in a [[cannabis]]-derived pharmaceutical formulation marketed by [[GW Pharmaceuticals]] as '''Epidiolex'''. Other CBD formulations remain Schedule I, except for those derived from hemp which are unscheduled but still FDA-regulated.<ref name="fda-apr2019">{{cite web |title=FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers |url=https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers |archive-url=https://web.archive.org/web/20190429051623/https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-questions-and-answers |url-status=dead |archive-date=April 29, 2019 |publisher=US Food and Drug Administration |access-date=May 18, 2019 |date=April 2, 2019}}</ref>